This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Humana (HUM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
by Zacks Equity Research
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
Here's What Key Metrics Tell Us About Humana (HUM) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
by Moumi Mondal
CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.
Humana (HUM) Q2 Earnings Lag Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of -0.79% and +1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Curious about Humana (HUM) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Humana (HUM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
by Zacks Equity Research
HUM's second-quarter earnings are likely to have witnessed strength in insurance premiums and Medicare, partly offset by rising costs and membership declines.
UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?
by Kaibalya Pravo Dey
UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.
UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?
by Kaibalya Pravo Dey
UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
by Moumi Mondal
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
by Kaibalya Pravo Dey
UNH and peers tumble as Medicaid cuts, enrollment shifts and rising costs shake up the managed care sector.
Humana Expands Medicaid Footprint With Virginia's Cardinal Care Win
by Zacks Equity Research
Cardinal Care taps HUM to offer its Healthy Horizons Medicaid plan, unlocking new growth in Virginia's healthcare market.
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
UnitedHealth Dropped From Russell Growth: How to Trade UNH Now
by Kaibalya Pravo Dey
UNH's removal from key Russell growth indices caps a turbulent stretch marked by steep losses, rising costs and regulatory woes.
Zacks Industry Outlook Highlights Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
CNC, MOH, CI, and HUM are set to benefit from Medicare demand, steady premiums, and tech-driven growth in the HMO space.
4 HMO Stocks Set to Thrive From Steady Premium Flows, M&A Strategy
by Debasmita Chatterjee
Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Is AI the Key to UnitedHealth's Market Growth and Cost Control?
by Kaibalya Pravo Dey
UNH ramps up AI use to cut costs, boost efficiency, and reshape healthcare workflows, but legal risks remain.
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
by Moumi Mondal
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
Can Optum Offset UnitedHealth's Health Benefits Growth Woes?
by Zacks Equity Research
Optum drives growth for UNH as rising Medicare Advantage costs pressure its health benefits unit.
UnitedHealth's Medical Membership Rises: Can It Maintain the Momentum?
by Zacks Equity Research
UNH's medical membership tops 50M amid rising demand. However, high Medicare costs cloud its growth outlook.
UnitedHealth to Curtail Medicare Advantage Costs: Margin Boost Ahead?
by Zacks Equity Research
UNH's CEO pledges reform after rare earnings miss as rising Medicare Advantage costs squeeze margins and spook investors.